 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: atezizumab plus bevacizumab for advanced mucosal melanoma

Clin Cancer Res: atezizumab plus bevacizumab for advanced mucosal melanoma

 Last Update: 2022-09-07
 Source: Internet
 Author: User

Tags

1 2 copper

hydrochlorothiazide 25 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Anti-programmed cell death-1 antibody monotherapy is part of the standard therapy for cutaneous melanoma but is less

This is a multicentric, open-label, one-arm Phase 2 study featuring Simon's two-phase design

Overall, a total of 43 patients were enrolled, including 20 (46.

90.

In conclusion, the combination therapy of atezizumab and bevacizumab has shown promising efficacy and controllable safety

Original source:

Lili Mao, Meiyu Fang, Yu Chen, et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.